Andorra vs Early-demographic dividend: Immunization, Hib3
Andorra
98.0%
in 2024
Early-demographic dividend
86.1%
in 2024
Andorra rank
20th
Early-demographic dividend rank
17th
Immunization, Hib3 over time
- Andorra
- Early-demographic dividend
How they compare
Andorra currently reports 98.0% against 86.1% in Early-demographic dividend, a difference of 11.9%.
That makes Andorra's figure about 1.1 times Early-demographic dividend's.
Across all 27 years both countries report, Andorra has been ahead every year.
Andorra ranks 20th and Early-demographic dividend ranks 17th of 191 countries.
Andorra has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Andorra | Early-demographic dividend | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 67.5% | 1.2% | 66.3% | Andorra |
| 2000s | 94.0% | 14.7% | 79.3% | Andorra |
| 2010s | 97.9% | 61.9% | 36.0% | Andorra |
| 2020s | 97.6% | 84.4% | 13.2% | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Andorra or Early-demographic dividend?
- Andorra, at 98.0% against 86.1% in Early-demographic dividend as of 2024.
- What is the difference in immunization, hib3 between Andorra and Early-demographic dividend?
- 11.9%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Early-demographic dividend?
- 27 years are reported by both, from 1998 to 2024.
- How do Andorra and Early-demographic dividend rank globally for immunization, hib3?
- Andorra ranks 20th and Early-demographic dividend ranks 17th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.